Advanced Tissue Sciences
This article was originally published in The Gray Sheet
Executive SummaryFDA requests clarification and additional information from ATS regarding its premarket approval application for Dermagraft for the treatment of diabetic foot ulcers, according to a Feb. 21 company release. The PMA was submitted in August 2000. Upon approval, Dermagraft will be marketed by Smith & Nephew (1"The Gray Sheet" Aug. 28, 2000, In Brief)
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.